Selected data models

You must log in to select data models for download or further analysis.

55 Search results.
Relevance Rating New first Old first

GSK Study Unscheduled Visit HEMATOLOGY AND CLINICAL CHEMISTRY LOCAL NCT00079911

- 4/6/22 - 1 form, 3 itemgroups, 30 items, 1 language
Itemgroups: Study administration, HEMATOLOGY, CLINICAL CHEMISTRY
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count 100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Study Unscheduled Visit HEMATOLOGY AND CLINICAL CHEMISTRY LOCAL NCT00079911

- 4/6/22 - 1 form, 3 itemgroups, 30 items, 1 language
Itemgroups: Study administration, HEMATOLOGY, CLINICAL CHEMISTRY
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count 100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons SERIOUS ADVERSE EVENTS NCT00079911

- 9/20/21 - 1 form, 13 itemgroups, 54 items, 1 language
Itemgroups: Study administration, SERIOUS ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, Seriousness, Demography Data, INSTRUCTIONS FOR COMPLETING SERIOUS ADVERSE EVENT FORMS, Possible Causes of SAE Other Than lnvestigational Products, RELEVANT Medical Conditions, Other RELEVANT Risk Factors, RELEVANT Concomitant Medications, Details of lnvestigational Products, Details of RELEVANT Assessments, Narrative Remarks
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

Infection NCT00513526 - Demographic - AMC-052 Demographic Form (DEM) 2676987_v1_0 - AMC-052 Demographic Form (DEM)

- 9/17/21 - 1 form, 1 itemgroup, 7 items, 2 languages
Itemgroup: Demographics
AMC-052 Demographic Form (DEM) Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=395422A0-6091-42B3-E044-0003BA3F9857

Eligibility DRKS00005163 NCT01134939 HIV Infections - Eligibility

- 9/17/21 - 1 form, 2 itemgroups, 14 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01207388

Eligibility HIV Infections NCT00192621

- 9/2/21 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00192621

Eligibility HIV-Associated Lipodystrophy Syndrome NCT00192660

- 9/2/21 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001); ODM derived from: https://clinicaltrials.gov/show/NCT00192660

Eligibility HIV Infections NCT00227500

- 9/2/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pravastatin for Hyperlipidaemia in HIV.; ODM derived from: https://clinicaltrials.gov/show/NCT00227500

Eligibility HIV NCT01886638

- 2/29/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Determining the Effect of Abacavir on Platelet Activation; ODM derived from: https://clinicaltrials.gov/show/NCT01886638

Eligibility HIV NCT01258439

- 2/29/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.; ODM derived from: https://clinicaltrials.gov/show/NCT01258439

Eligibility HIV NCT01049789

- 2/29/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Treatment for Depression Among HIV-Infected Youth; ODM derived from: https://clinicaltrials.gov/show/NCT01049789

Eligibility HIV Infections NCT02190305

- 2/29/20 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Rapid Diagnostics for HIV and Hepatitis; ODM derived from: https://clinicaltrials.gov/show/NCT02190305

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial